Targeted Therapy Finder

CollabRx apps discussed in the British Journal of Healthcare Computing

The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy […]

Cancer Commons Researchers Publish Molecular Disease Model for Lung Cancer

PALO ALTO, Calif.–(BUSINESS WIRE)–Cancer Commons, an open‐science initiative to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model (MDM) for lung cancer. The paper, by Lisandra West, Ravi Salgia, and others will appear in the February 21st issue of PLoS ONE.

CollabRx partners with The College of American Pathologists Partners to Provide Personalized Decision Tools to Cancer Patients

The College of American Pathologists (CAP) announced today its partnership with CollabRx to provide patients with advanced stage lung or skin cancer access to the cutting-edge information on cancer therapies that could change their lives. Patients can now download the CollabRx Targeted Therapy Finder apps through the College’s website, and their patient portal,, to find the latest information on diagnostic tests, clinical trials, […]

Lung Cancer Molecular Disease Model Published in PLoS ONE

A team including leading lung cancer researchers, and CollabRx scientists, has just published a novel Lung Cancer Molecular Disease Model in PLoS ONE, a leading peer-reviewed open source journal. (

CollabRx Launches New Lung Cancer Clinical Decision Support Tool for Patients and Oncologists, Appoints New CEO

Source: CollabRx Inc. — New Targeted Therapy Finder-Lung Cancer transforms current understanding of lung cancer into personalized and actionable treatment recommendations — Healthcare and Pharma Veteran James Karis joins as company expands its “app”-centric approach to new cancers PALO ALTO, Calif.–(BUSINESS WIRE)–CollabRx, the company that leverages information technology to inform personalized cancer treatment planning, announces […]

PLoS ONE: A Melanoma Molecular Disease Model

Peer Reviewed Molecular Disease Models While advanced melanoma remains one of the most challenging cancers, recent developments in our understanding of the molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapeutic decisions. Genetic analyses of melanoma have uncovered several key molecular pathways that are involved in disease onset and progression, as well as prognosis. […]